Why Are People Talking About Investing in SRPT?

By Harris Dyer • Tuesday, October 10 15:26 • Permanent Link

Join us for a quick overview of Sarepta Therapeutics, a Pharmaceutical company whose shares moved -0.9% today. Here are some facts about the stock that should help you see the bigger picture:

Sarepta Therapeutics has moved 12.0% over the last year, and the S&P 500 logged a change of 23.0%
SRPT has an average analyst rating of buy and is -32.29% away from its mean target price of $180.61 per share
Its trailing earnings per share (EPS) is $-10.47
Sarepta Therapeutics has a trailing 12 month Price to Earnings (P/E) ratio of -11.7 while the S&P 500 average is 15.97
Its forward earnings per share (EPS) is $3.75 and its forward P/E ratio is 32.6
The company has a Price to Book (P/B) ratio of 15.39 in contrast to the S&P 500's average ratio of 2.95
Sarepta Therapeutics is part of the Health Care sector, which has an average P/E ratio of 24.45 and an average P/B of 4.16
The company has a free cash flow of $-162265744, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; and AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program that is under Phase 1/2a clinical trial; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Selecta Biosciences; Hansa Biopharma; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.